Ria Health Raises Growth Capital to Accelerate Access to Patient-Driven AUD Treatment
2024 SV Therapeutics Impact & ESG Report
Read More
Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas
Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System
SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise
Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure
Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
Read More
SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion
Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation
QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
- 30 March 2022SV NewsKate Bingham shared the key lessons learnt from the success of the UK Vaccine Taskforce at The Royal Society’s recent Science of COVID-19 event.
24 March 2022Portfolio NewsImbria Pharmaceuticals Appoints John Young to its Board of Directors
19 March 2022Portfolio NewsLoQus23: going upstream to slow Huntington’s disease
8 March 2022Portfolio NewsTRexBio Completes $26 Million Series A Extension Led by Polaris Partners to Advance Treatments for Immune-Mediated Diseases- 8 March 2022Portfolio NewsPionyr Immunotherapeutics Doses First Patient in Phase 1b Expansion Study of PY314
- 2 March 2022Portfolio NewsCaraway Therapeutics Expands Scientific Advisory Board with the Appointment of David Clapham, MD, PhD
2 March 2022Portfolio NewsRondo Therapeutics Closes $67 Million Series A Financing to Advance Next-Generation Immuno-Oncology Platform for Solid Tumors- 22 February 2022Portfolio NewsEyeBio Raises $65M in Series A Funding to Develop New Generation of Eye Disease Therapies
- 25 January 2022Portfolio NewsLoQus23 Therapeutics appoints Dr. Melanie Ivarsson, OBE, as Non-Executive Director
- 6 January 2022Portfolio NewsSV Created TRexBio Announces Collaboration with Janssen to Discover Novel Targets for Immunology and Inflammation
5 December 2021SV NewsKate Bingham FT op-ed: Covid has given UK biotech a lesson — and a legacy
29 November 2021Portfolio NewsQuell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform
